PANAKÈS PARTNERS

Website statement – Financial Product

Website product disclosure for financial products referred to in Article 8(1), (2) and (2a) of Regulation (EU) 2019/2088

BII Catalyst Fund I for Italy – SFDR Website Disclosure[1]

Legal entity identifier: 81560084DAA6DB04B422

a) Summary

BII Catalyst Fund I for Italy ("BCFII" or the "Fund") is a closed-end venture capital fund qualifying under the EuVECA Regulation. It focuses on early-stage bioscience companies in the research phase with limited access to capital, scouting opportunities from the pre-incorporation, pre-seed and seed stages. Its scope covers human health, with a prevailing focus on therapeutics (biologics, small molecules, cell therapies), as well as therapeutic medical technologies, diagnostics and prognostics, and related enabling solutions, including AI and quantum approaches to drug discovery.

The Fund is managed by Panakès Partners SGR S.p.A. ("Panakès" or the "AIFM"). It is advised by BII Catalyst AIFM ApS, linked to the BioInnovation Institute in Copenhagen, which supports deal scouting, business planning and due diligence; selected companies also gain access to the BioInnovation Institute's innovation platform. From incorporation onwards, Panakès supports founders in building companies that address unmet medical needs and in embedding responsible practices from the start, proportionately to their size and stage of development. The Fund promotes environmental and social characteristics: efficient use of resources, responsible waste management, responsible workforce management, health and safety, ethically oriented R&D and patient-centred innovation. These are measured through 23 Sustainability Indicators covering environmental, social and governance topics.

The Fund does not invest in the sectors excluded under the Fund Rules and under Panakès's Exclusion List. Before every investment, Panakès carries out a dedicated ESG Due Diligence based on a materiality analysis following the SASB sector approach. It identifies material sustainability risks and opportunities, such as environmental and climate risks, laboratory and

[1] Legal basis: Article 10(1) of Regulation (EU) 2019/2088 (SFDR) – transparency of the promotion of environmental or social characteristics on websites – and Chapter IV, Section 1 (Articles 23–36) of Commission Delegated Regulation (EU) 2022/1288 (RTS), as amended by Delegated Regulation (EU) 2023/363.

research waste, health and safety, bioethics and animal welfare, data protection and governance practices. Panakès monitors portfolio companies annually through a dedicated ESG questionnaire and ongoing dialogue, including through its participation in their governance bodies. It reports the results to investors in an Annual ESG Report.

BII Catalyst Fund I for Italy ("BCFII" o il "Fondo") è un fondo di venture capital di tipo chiuso, qualificato ai sensi del Regolamento EuVECA. Il Fondo è focalizzato su società early-stage nel settore delle bioscienze, in fase di ricerca e con limitato accesso ai capitali, e svolge attività di scouting dalle fasi di pre-incorporation, pre-seed e seed. L'ambito di investimento comprende la salute umana, con focus prevalente sui farmaci terapeutici (biologics, small molecules, terapie cellulari), oltre a tecnologie mediche terapeutiche, diagnostica e prognostica, e progetti e servizi di supporto connessi, incluse soluzioni di intelligenza artificiale e quantistiche per la scoperta di farmaci.

Il Fondo è gestito da Panakès Partners SGR S.p.A. ("Panakès" o la "Società di Gestione"). Si avvale della consulenza di BII Catalyst AIFM ApS, collegata al BioInnovation Institute di Copenaghen, che supporta lo scouting delle opportunità di investimento, la predisposizione dei business plan e la due diligence; le società selezionate accedono inoltre alla piattaforma di innovazione del BioInnovation Institute. Fin dalla costituzione, Panakès affianca i fondatori nel costruire società che rispondano a bisogni medici non soddisfatti e nell'integrare pratiche responsabili sin dall'inizio, in modo proporzionato alla loro dimensione e al loro stadio di sviluppo. Il Fondo promuove caratteristiche ambientali e sociali: uso efficiente delle risorse, gestione responsabile dei rifiuti, gestione responsabile della forza lavoro, salute e sicurezza, ricerca e sviluppo eticamente orientate e innovazione orientata al paziente. Tali caratteristiche sono misurate tramite 23 Indicatori di Sostenibilità relativi a temi ambientali, sociali e di governance.

Il Fondo non investe nei settori esclusi ai sensi del Regolamento del Fondo e della Exclusion List di Panakès. Prima di ogni investimento, Panakès svolge una Due Diligence ESG dedicata, basata su un'analisi di materialità secondo l'approccio settoriale del SASB. La Due Diligence individua rischi e opportunità di sostenibilità rilevanti, quali i rischi ambientali e climatici, i rifiuti di laboratorio e di ricerca, la salute e sicurezza, la bioetica e il benessere animale, la protezione dei dati e le prassi di governance. Panakès monitora annualmente le società in portafoglio tramite un questionario ESG dedicato e un dialogo continuativo, anche attraverso la partecipazione ai loro organi di governance, e ne rendiconta i risultati agli investitori nella Relazione Annuale ESG.

b) No sustainable investment objective[2]

This financial product promotes environmental or social characteristics, but does not have as its objective sustainable investment and will not make any sustainable investment within the meaning of Article 2(17) SFDR. Its investments are not assessed for alignment with the EU Taxonomy.

[2] Article 24(b) and Article 26 RTS. The statement required by Article 26 RTS is: 'This financial product promotes environmental or social characteristics, but does not have as its objective sustainable investment.' 'Sustainable investment' as defined in Article 2(17) SFDR.

c) Environmental or social characteristics of the financial product[3]

The Fund promotes environmental and social characteristics through a responsible investment approach that integrates ESG criteria across the whole investment cycle. Given the early-stage nature of the portfolio companies, this integration is proportionate to each company's size, operational maturity and stage of development.

Environmental characteristics. The Fund promotes the progressive adoption of environmentally responsible business practices, where relevant to the company's activity and stage of development:

1. Efficient use of resources, with attention to the responsible management of materials, energy and other relevant operating resources.
2. Responsible waste management, including, where applicable, waste reduction and waste from laboratory, research, development or production activities.
3. Consideration of material environmental and climate risks, depending on the nature of the activity, the operating model and the development stage of the company.

Social characteristics. The Fund promotes social characteristics linked to responsible human capital management, healthcare innovation and the ethical conduct of research and development:

1. Responsible workforce management, including diversity, inclusion and equal opportunities.
2. Health, safety and well-being of employees, taking into account the nature of the activities carried out.
3. Development, engagement and retention of staff, with particular attention to skills growth and the ability to attract and retain qualified talent.
4. Responsible innovation and ethically oriented R&D, including, where relevant, bioethics, patient safety, clinical responsibility and animal welfare.
5. Patient-centred innovation, through solutions addressing relevant clinical needs and/or improving the efficiency of care pathways.

Governance. In support of these characteristics, the AIFM also assesses and monitors governance and responsible business conduct at portfolio companies. It promotes the progressive adoption of good governance practices, proportionate to each company's size and stage, and the responsible management of data and information security, with attention to data protection, privacy and cybersecurity awareness.

[3] Article 10(1)(a) SFDR; Article 24(c) and Article 27 RTS (description of the environmental or social characteristics promoted); Article 8(1) SFDR.

d) Investment strategy[4]

The Fund invests in Eligible Companies, as defined in the Fund Rules, mainly early-stage companies in life sciences and human health (therapeutics, medical technologies, diagnostics and prognostics). ESG criteria are integrated throughout the investment process, proportionately to each company's size and stage of development.

The Fund does not invest in companies operating in the Excluded Sectors and before each investment, the AIFM performs a mandatory ESG Due Diligence checklist.

The Fund invests only in companies that, following the ESG Due Diligence, are consistent with the characteristics promoted or show ESG improvement potential, and that follow good governance practices or are able to adopt proportionate ones. Where material ESG issues emerge that cannot be mitigated, the AIFM does not proceed with the investment.

The Fund does not apply a predetermined minimum rate to reduce the scope of investments considered.

Assessment of good governance practices. Good governance is assessed during the ESG Due Diligence and monitored during the holding period, in line with the Responsible Investment Policy. The AIFM considers, proportionately to each company's size and stage, sound management structures, employee relations, remuneration of staff and tax compliance, as well as business ethics, conflict-of-interest prevention and data protection.

e) Proportion of investments

All of the Fund's investments (100%) are aligned with the environmental and social characteristics it promotes; none are sustainable investments.

All investments are direct exposures to portfolio companies. The Fund does not use derivatives to attain the characteristics promoted.

f) Monitoring of environmental or social characteristics[5]

The AIFM monitors the characteristics promoted throughout the life of each investment, mainly through an annual ESG questionnaire and continuous dialogue with portfolio companies. It aims to monitor every portfolio company annually, considering data availability, the materiality of ESG issues and the company's size and maturity. Not all indicators are collected at Due Diligence; some are assessed progressively through annual monitoring.

---

[4] Article 24(d) and Article 28 RTS: description of the investment strategy used to attain the characteristics promoted and of the policy to assess good governance practices of the investee companies, including with respect to sound management structures, employee relations, remuneration of staff and tax compliance (see also Article 8(1) SFDR).

[5] Article 24(f) and Article 30 RTS: how the environmental or social characteristics and the sustainability indicators are monitored throughout the lifecycle of the financial product, and the related internal or external control mechanisms.

Control mechanisms. Monitoring is coordinated by the ESG Manager, who collects and reviews the data and supports portfolio companies in their reporting. Results are discussed by the ESG Committee, which meets at least quarterly, and reported to the Board of Directors, which oversees the application of the Responsible Investment Policy. The AIFM may also rely on an external ESG expert (Fund Rules, par. 4.7.4).

The Sustainability Indicators below are used, by way of example and not exhaustively, to measure attainment of each characteristic.

Area	Characteristic	Sustainability indicator
Environmental	Efficient use of resources	% of portfolio companies monitoring energy consumption
Environmental	Efficient use of resources	% of portfolio companies with energy-efficiency or consumption-reduction initiatives
Environmental	Waste management	% of portfolio companies with waste reduction, management or recycling initiatives
Environmental	Environmental and climate risks	Presence of environmental policies, procedures or initiatives proportionate to the activity
Social	Workforce management	Total number of employees and contractors
Social	Workforce management	Staff turnover rate
Social	Diversity and inclusion	Gender diversity in the workforce, management and board
Social	Diversity and inclusion	% of portfolio companies with diversity, equal opportunity, anti-discrimination or anti-harassment policies
Social	Health, safety and well-being	% of portfolio companies with health and safety policies or procedures
Social	Health, safety and well-being	Number of workplace incidents and related corrective or mitigating actions
Social	Health, safety and well-being	% of portfolio companies with employee well-being initiatives
Social	Talent development and retention	Presence of performance review, skills development, training or career plans
Social	Ethical R&D	% of preclinical-stage companies applying animal

Area	Characteristic	Sustainability indicator
		welfare standards or procedures
Social	Ethical R&D	% of companies with policies or safeguards on bioethics, research integrity, patient safety or clinical responsibility
Social	Patient-centred innovation	% of portfolio companies developing products or services for unmet medical needs or to improve care pathways
Governance	Business conduct	% of portfolio companies with a Code of Ethics or Code of Conduct
Governance	Business conduct	% of portfolio companies with business ethics, anti-corruption, conflict-of-interest or integrity policies
Governance	Business conduct	% of portfolio companies with reporting, whistleblowing or grievance channels, where proportionate
Governance	Data security	% of portfolio companies with data protection and information security measures
Governance	Data security	% of portfolio companies providing data protection, privacy or cybersecurity training
Governance	Regulatory compliance	% of relevant portfolio companies with product or regulatory compliance processes
Governance	ESG oversight	% of portfolio companies with ESG oversight at board or management level
Governance	ESG oversight	% of portfolio companies with an ESG contact person or function

In addition, the AIFM may carry out qualitative assessments of climate risks, environmental topics, social aspects and healthcare-specific impact considerations, where relevant and proportionate.

g) Methodologies[6]

Attainment of the characteristics is measured through the Sustainability Indicators above. Binding elements are verified for every investment at the ESG Due Diligence stage (exclusion screening, ESG

[6] Article 10(1)(b) SFDR; Article 24(g)–(i) and Articles 31 (Methodologies), 32 (Data sources and processing: data sources, measures to ensure data quality, data processing, proportion of estimated data) and 33 (Limitations to methodologies and data) RTS.

consistency, good governance). Company-level indicators are aggregated at portfolio level, mostly as the percentage of portfolio companies meeting each indicator, and tracked over time to identify improvements or regressions. Panakès uses an ESG questionnaire (based on the Life Science VC Sustainability Initiative framework), in which material sustainability factors are prioritised through a materiality analysis following the sector approach of the Sustainability Accounting Standards Board (SASB).

h) Data sources and processing

Data come mainly from portfolio companies, through the ESG Due Diligence checklist, the annual ESG questionnaire, documents provided under contractual information rights and ongoing dialogue with management and boards. Where available, the AIFM also uses the results of checks or assessments carried out by third parties. The AIFM reviews the data for completeness and consistency and follows up with companies where needed. The AIFM does not currently use estimated data: all data are reported by portfolio companies or derived from documents they provide.

i) Limitations to methodologies and data

Portfolio companies are mostly early-stage, with small teams, limited operational footprints and limited ESG data. Data are largely self-reported and not externally assured, and some indicators may not be available or relevant for every company or stage. To manage these limits, the AIFM applies a proportionate approach, collects some indicators progressively, and supports companies in improving data quality over time. These limitations do not prevent the Fund from promoting its characteristics, which rely primarily on binding elements applied to every investment (exclusions, mandatory ESG Due Diligence and good governance assessment) and on most indicators measuring the presence of policies and procedures that early-stage companies can report.

j) Due diligence[7]

Before each investment, the AIFM performs an ESG Due Diligence on the target company, in line with the Responsible Investment Policy, verifying:

1. the application of the exclusion criteria set out in the Fund Rules and in Panakès's Exclusion List;
2. material Sustainability Risks;
3. the investment's contribution to the environmental and social characteristics promoted;
4. good governance practices, or the ability to adopt proportionate ones.

The due diligence process is proportionate to the target company's size, operating model, sector and stage of development, and is conducted using the ESG checklist. Its results are integrated into the

[7] Article 24(j) and Article 34 RTS: description of the due diligence carried out on the underlying assets, including the internal and external controls on that due diligence.

overall risk assessment and presented to the Board of Directors. The risks and improvement areas identified become the starting point for the company's ESG Action Plan.

k) Engagement policies[8]

Throughout the holding period, Panakès engages with portfolio companies to support the progressive adoption of ESG practices and their integration into operations, governance and strategy, proportionately to each company's size and stage of development. Engagement takes place mainly through regular dialogue with management and the Fund's participation in the companies' governance bodies, supported by the information and monitoring rights agreed at investment; ESG-related commitments may also be included in the investment documentation. Where appropriate, improvement areas identified in the Due Diligence or in the annual monitoring may be addressed through targeted actions agreed with the company, which may take the form of an ESG Action Plan.

Where monitoring identifies potential negative effects or regressions, Panakès assesses their significance and works with the company to address them by updating its ESG Action Plan.

Sustainability-related controversies. Through the annual ESG questionnaire, the AIFM identifies past and ongoing controversies relating to environmental, social or governance issues at each portfolio company. Significant cases are discussed with management, appropriate mitigation measures are agreed, and their implementation is followed up as part of the ongoing monitoring.

This collaborative approach aims to create long-term sustainable value for investors, portfolio companies, patients, healthcare systems and society as a whole.

More information about engagement activities is included in the Responsible Investment policy.

l) Designated reference benchmark[9]

No index has been designated as a reference benchmark to attain the environmental or social characteristics promoted by the Fund.

[8] Article 24(k) and Article 35 RTS: where engagement is part of the environmental or social investment strategy, description of the engagement policies, including any management procedures applicable to sustainability-related controversies in investee companies.

[9] Article 24(l) and Article 36 RTS; Article 8(1)(b) SFDR.